IQV

AI Memo

IQVIA

As of 2026-09-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 execution and raised FY2026 guidance • 2026-07-28

Base target: $277 / p=55% prob

Biggest risk

The thesis remains sensitive to CRO demand durability, backlog conversion, margin pressure, elevated debt, and execution. GAAP earnings were weaker than adjusted results, while verified post-print analyst revisions and target changes are unavailable.

Invalidation

Break below $225 or thesis failure.

What would change my mind?

Strong Q2 revenue and adjusted EPS growth, record R&D bookings, backlog visibility, improving AI adoption, and raised FY2026 guidance support continued execution into 2027 [#SEC-8K-2026-07-28].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-02

Base target

$277

p=55%

Bull target

$300

p=25%

Bear target

$225

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Backlog conversion and bookings durability
Commercial AI adoption and durable R&D demand
Strong Q2 revenue and adjusted EPS growth, record R&D bookings, backlog visibility, improving AI adoption, and raised FY2026 guidance support continued execution into 2027 [#SEC-8K-2026-07-28].

BearKey bullets

Higher cost of revenues, selling and administrative expense, restructuring costs, and interest expense could constrain GAAP earnings and margins.
Leverage remains material; stored earnings context reports approximately $16 billion of debt and 3.59x net leverage [#PR-EARNINGS-2026-08-27].
R&D Solutions bookings and backlog may not convert at the indicated pace.

WatchKey bullets

Q2 execution and raised FY2026 guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $277 (p=55%)

Target spread vs base: +8% / -19%

Scenario probabilities

Bull Target: $300 (p=25%)Base Target: $277 (p=55%)Bear Target: $225 (p=20%)

Commentary

Primary-company evidence is constructive after Q2 execution, higher bookings, backlog visibility, and raised FY2026 guidance [#SEC-8K-2026-07-28]. Stored secondary earnings context reports shares were up about 5.6% since the last earnings report, but detailed reaction attribution and analyst revisions are unavailable. Social coverage is unavailable, so confidence remains moderate.

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Strong Q2 revenue and adjusted EPS growth, record R&D bookings, backlog visibility, improving AI adoption, and raised FY2026 guidance support continued execution into 2027 [#SEC-8K-2026-07-28].

Bear Case

Drivers

Scannable catalysts and supporting factors

Backlog conversion and bookings durability
Commercial AI adoption and durable R&D demand

Scenarios

Bull Target (Scenario probability)

$300 / p=25% prob

Base Target (Scenario probability)

$277 / p=55% prob

Bear Target (Scenario probability)

$225 / p=20% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-28
Q2 execution and raised FY2026 guidance
IQVIA reported Q2 revenue of $4.368 billion, adjusted diluted EPS of $3.15, adjusted EBITDA of $994 million, and raised full-year 2026 revenue, EBITDA, and EPS guidance [#SEC-8K-2026-07-28].
Prob 95.00% • Move 6.00% • Priced-in 85.00%

Short-term Catalysts

Next few weeks

Backlog conversion and bookings durability
2026-12-31
R&D Solutions delivered 19% year-over-year net-new-bookings growth, a 1.22x book-to-bill ratio, and $34.2 billion of contracted backlog; approximately $9.2 billion is expected to convert to revenue over the next twelve months [#SEC-8K-2026-07-28].
Prob 70% • Move 7% • Priced-in 55%

Long-term Catalysts

Months to a year

Commercial AI adoption and durable R&D demand
2027-06-30
Management cited increased adoption of AI-enabled offerings and favorable forward demand indicators across both segments; sustained adoption and bookings execution could support a longer-term rerating [#SEC-8K-2026-07-28].
Prob 60% • Move 10% • Priced-in 45%

Risks

Higher cost of revenues, selling and administrative expense, restructuring costs, and interest expense could constrain GAAP earnings and margins.
Leverage remains material; stored earnings context reports approximately $16 billion of debt and 3.59x net leverage [#PR-EARNINGS-2026-08-27].
R&D Solutions bookings and backlog may not convert at the indicated pace.
Recent Form 4 filings show multiple officer open-market sales, which may weigh on sentiment but do not establish an operating deterioration signal [#SEC-FORM4-2026-08-04] [#SEC-FORM4-2026-07-31].
Recent news coverage is sparse, and verified analyst estimate, rating, or price-target revisions after the Q2 release are unavailable.

Peers

Symbol	Summary
ICLR	Direct global CRO comparator relevant to sponsor demand, bookings quality, and clinical-research execution.
FTRE	Direct CRO comparator relevant to outsourced clinical-development demand and margin execution.
CRL	Direct clinical-research and life-sciences services comparator for research-services demand and execution.
MEDP	Direct clinical-research comparator useful for benchmarking CRO growth and operating performance.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

ICLR

Direct global CRO comparator relevant to sponsor demand, bookings quality, and clinical-research execution.

FTRE

Direct CRO comparator relevant to outsourced clinical-development demand and margin execution.

CRL

Direct clinical-research and life-sciences services comparator for research-services demand and execution.

MEDP

Direct clinical-research comparator useful for benchmarking CRO growth and operating performance.